|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma |
|||||||||||
|
|
|||||||||||
|
1 November 2021
AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). |
|||||||||||
|